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It has been suggested that in comparison with open radical cystectomy, robotic-assisted radical 
cystectomy results in less blood loss, shorter convalescence, and fewer complications with equivalent 








Review authors conducted a comprehensive search with no restrictions on language of publication or 
publication status for studies comparing open radical cystectomy and robotic-assisted radical 
cystectomy. The date of the last search was 1 July 
2018 for the Cochrane Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed 
Embase (1999 to July 2018), Web of Science (1999 to July 2018), Cancer Research UK 
(www.cancerresearchuk.org/), and the Institute of Cancer Research (www.icr.ac.uk/). We searched 
the following trials registers: ClinicalTrials.gov (clinicaltrials.gov/), BioMed Central International 
Standard Randomized Controlled Trials Number (ISRCTN) Registry (www.isrctn.com), and the World 
Health Organization International Clinical Trials Registry Platform. 
 
Selection criteria 
We searched for randomised controlled trials that compared robotic-assisted radical cystectomy 
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Data collection and analysis 
This study was based on a published protocol. Primary outcomes of the review were recurrence-free 
survival and major postoperative complications (class III to V). Secondary outcomes were minor 
postoperative complications (class I and II), transfusion requirement, length of hospital stay (days), 
quality of life, and positive margins (%). Three review authors independently assessed relevant titles 
and abstracts of records identified by the literature search to determine which studies should be 
assessed further. Two review authors assessed risk of bias using the Cochrane risk of bias tool and 
rated the quality of evidence according to GRADE. We used Review Manager 5 to analyse the data. 
 
Main results 
We included in the review five randomised controlled trials comprising a total of 541 
participants. Total numbers of participants included in the ORC and RARC cohorts were 270 
and 271, respectively. 
 
Primary outomes 
Time-to-recurrence: Robotic cystectomy and open cystectomy may result in a similar time to 
recurrence (hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.77 to 1.43); 2 trials; low-certainty 
evidence). In absolute terms at 5 years of follow-up, this corresponds to 16 more recurrences per 
1000 participants (95% CI 79 fewer to 123 more) with 431 recurrences per 1000 participants for ORC. 
We downgraded the certainty of evidence for study limitations and imprecision. 
 
Major complications (Clavien grades 3 to 5): Robotic cystectomy and open cystectomy may result in 
similar rates of major complications (risk ratio (RR) 1.06, 95% CI 0.76 to 1.48); 5 trials; low-certainty 
evidence). This corresponds to 11 more major complications per 1000 participants (95% CI 44 fewer to 
89 more). We downgraded the certainty of evidence for study limitations and imprecision. 
 
Secondary outcomes 
Minor complications (Clavien grades 1 and 2): We are very uncertain whether robotic 
cystectomy may reduce minor complications (very low-certainty evidence). We downgraded the 
certainty of evidence for study limitations and for very serious imprecision. 
 
Transfusion rate: Robotic cystectomy probably results in substantially fewer transfusions than open 
cystectomy (RR 0.58, 95% CI 0.43 to 0.80; 2 trials; moderate-certainty evidence). This corresponds to 
193 fewer transfusions per 1000 participants (95% CI 262 fewer to 92 fewer) based on 460 transfusion 
per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations. 
Hospital stay: Robotic cystectomy may result in a slightly shorter hospital stay than open cystectomy 
(mean difference (MD) 
-0.67, 95% CI -1.22 to -0.12); 5 trials; low-certainty evidence). We downgraded the certainty of 
evidence for study limitations and imprecision. 
Quality of life: Robotic cystectomy and open cystectomy may result in a similar quality of life 
(standard mean difference (SMD) 0.08, 95% CI 0.32 lower to 0.16 higher; 3 trials; low-certainty 
evidence). We downgraded the certainty of evidence for study limitations and imprecision. 
Positive margin rates: Robotic cystectomy and open cystectomy may result in similar positive margin 
rates (RR 1.16, 95% CI 0.56 to 2.40; 5 trials; low-certainty evidence). This corresponds to 8 more (95% 
CI 21 fewer to 67 more) positive margins per 1000 participants based on 48 positive margins per 1000 
participants for ORC. We downgraded the certainty of evidence for study limitations and imprecision. 
Authors' conclusions 
 
Robotic cystectomy and open cystectomy may have similar outcomes with regard to time to recurrence, 
rates of major complications, quality of life, and positive margin rates (all low-certainty evidence). We 
are very uncertain whether the robotic approach reduces rates of minor complications (very low-
certainty evidence), although it probably reduces the risk of blood transfusions substantially (moderate-
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conduct any of the preplanned subgroup analyses to assess the impact of patient age, pathological 
stage, body habitus, or surgeon expertise on outcomes. This review did not address issues of cost-
effectiveness. 
 
Plain language summary 
Robotic versus open radical cystectomy for bladder cancer in adults 
Review question 
For patients with bladder cancer that involves the deep muscle wall, does use of a robotic device 
lead to better or worse outcomes than open surgery? 
Background 
Patients with bladder cancer that involves the deep muscle wall are best treated by an operation that 
removes the entire bladder and creates an artificial bladder or channel from the bowel to allow urine to 
drain to the outside world. This has been done traditionally through open surgery using one large 
incision. Recently, this operation has been performed with robotic assistance using several small 
incisions. It is uncertain which approach is better. 
Study characteristics 
We performed a comprehensive literature search until 1 July 2018. We found five trials comparing 
robotic assisted versus open surgery. The total number of participants in these trials was 541. Four 
studies were conducted in the USA and one in the UK. 
Key results 
There may be little to no difference in the time to recurrence, the rate of major complications or minor 
complications, quality of life, and rates of positive margins (signalling that cancer may have been left 
behind). Robotic surgery probably results in fewer blood transfusions and may lead to a slightly 
shorter hospital stay when compared with open surgery. 
Certainty of evidence 
Reviewers rated the certainty of evidence as low for most outcomes, except for minor 
complications (very low) and transfusions (moderate). This means that the true results for 




Description of the condition 
Over 400,000 new cases of bladder cancer are diagnosed annually, accounting for 3% of all cancers 
(Ferlay 2013; Ferlay 2015; Ploeg 2009). Radical cystectomy (RC) with pelvic lymph node dissection 
(PLND) and urinary diversion is the gold standard surgical treatment for muscle-invasive bladder 
cancer (MIBC) (Hayn 2010; Jonsson 2011; Lee 2011; Redorta 2010; Smith 2011; Witjes 2014). Other 
indications for RC include high-risk non-muscle-invasive bladder cancer (NMIBC) and recurrent 
multifocal superficial disease (Hayn 2010; Jonsson 2011; Lee 2011; Redorta 2010; Smith 2011; Witjes 
2014 
). The procedure has traditionally been performed using an open approach. Morbidity with 
open radical cystectomy (ORC) is high. In a retrospective review of a prospectively 
maintained database of 1142 patients who underwent ORC/urinary diversion by high-volume 
fellowship-trained urological oncologists, the reported 90-day overall complication rate and 
the 30-day mortality rate were 64% and 1.5%, respectively (Shabsigh 2009). 
Description of the intervention 
A significant interest in minimally invasive surgery (MIS) has arisen in the last two decades in an 
attempt to reduce morbidity, expedite recovery, and decrease hospital stay (Hu 2009; Schwenk 
2005; Wright 2013). MIS approaches, both conventional laparoscopy and robotic-assisted 
approaches, have replaced a significant number of open surgical techniques (Hu 2009; Schwenk 
2005; Wright 2013). The uptake of conventional laparoscopic radical 
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reconstructive aspects of the procedure (Aboumarzouk 2012; Aboumarzouk 2013; Castillo 2006; 
Castillo 2009; Cathelineau 2005; Haber 2008; Hosseini 2011; Huang 2008; Huang 2010; Jonsson 
2011; Khan 2011; Sighinolfi 2007; Smith 2011). 
Robotic-assisted radical cystectomy (RARC)—which offers such advantages as increased 
manoeuvrability, superior magnification, enhanced EndoWrist® dexterity, and tremor 
elimination—has been suggested as an alternative to overcome issues associated with the 
conventional laparoscopic approach (Ishii 2014). 
How the intervention might work 
Adoption of the robotic approach has been swift in contemporary urological practice, with 
widespread application of robotic-assisted radical prostatectomy and robotic-assisted partial 
nephrectomy in Europe and the USA leading to favourable perioperative outcomes in comparison 
with open and laparoscopic counterparts (Novara 2012). Three systematic reviews of randomised 
and nonrandomised controlled trials suggested shorter operative time and less blood loss for 
ORC when compared with RARC (Ishii 2014; Novara 2015; Tang 2014). These reviews also 
demonstrated reduced Clavien grade 3 complications for RARC. Two comparative studies have 
suggested similar survival outcomes between ORC and RARC (Khan 2012; Nepple 2013). 
Why it is important to do this review 
Although over 2000 procedures have been reported to the International Robotic Cystectomy 
Consortium from 37 centres worldwide, well-conducted studies comparing RARCs to ORCs are 
lacking (Raza 2015). Randomised controlled trials are necessary to establish how RARC 
compares to ORC. We performed a systematic review to summarise and 
critically appraise the body of evidence comparing these two approaches to inform clinical decision-
making as well as health policy. 
Objectives 
 
To assess the effects of robotic-assisted radical cystectomy versus open radical cystectomy in adults with 
bladder cancer. 
Methods 
Criteria for considering studies for this review 
Types of studies 
We included all randomised controlled trials (RCTs) and quasi-RCTs of individual participants 
comparing ORC and RARC. We did not include cluster-randomised trials. We considered all studies 
regardless of their publication status and language of publication. 
Types of participants 
We included adult participants with a diagnosis of bladder malignancy who were undergoing radical 
cystectomy as part of their treatment for pathologically proven MIBC or high-grade NMIBC (T1-
4/carcinoma in situ (CIS), N0M0). We included participants irrespective of histological bladder cancer 
type (i.e. we included those with urothelial cell carcinoma, squamous cell carcinoma, or 
adenocarcinoma). We included participants receiving neoadjuvant or adjuvant chemotherapy. We 
excluded studies of participants with prior radiotherapy in which cystectomy was performed as a 
salvage procedure. 
Types of interventions 
We investigated the following comparison of experimental intervention versus comparator 
intervention. We included trials independent of the urinary diversion method employed. We 
analysed data by intention-to-treat analysis. 
Experimental intervention 
Robotic-assisted radical cystectomy. 
Comparator intervention 
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Types of outcome measures 
Primary outcomes 
• Time to recurrence 
• Major postoperative complications (class III to V) (Dindo 2004) 
Secondary outcomes 
• Minor postoperative 
complications (class I and II) 
(Dindo 2004) Transfusion 
requirement 
• Length of hospital stay (days) 
• Quality of life as evaluated via validated participant-reported questionnaire scores or 
domains reflecting overall or global health of the participant 
• Positive margins (%) 
Search methods for identification of studies 
Electronic searches 
We performed a comprehensive search with no restrictions on language of publication nor publication 
status. We searched the following electronic databases (date of last search was 1 July 2018): 
• Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) in the Cochrane 
library via Wiley 
• MEDLINE (1999 to July 2018); PubMed search. We used these terms and medical 
subject heading (MeSH) phrases: (cystectomy [MeSH terms] AND robotic AND open) 
AND "surgery" [MeSH subheading] 
• EMBASE (1999 to July 2018); Ovid search using the terms 
cystectomy, open, and robotic 
• Web of Science (1999 to July 2018) 
• Cancer Research UK 
(www.cancerresearc
huk.org/)  
• Institute of Cancer 
Research 
(www.icr.ac.uk/) 







• BioMed Central ISRCTN registry (www.isrctn.com) 
• World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; 
www.who.int/ictrp/en/) 
See Appendix 1 for search terms used in strategies for this review. We limited back-
searching from 1999 onward because the earliest da Vinci robotic-assisted device was not 
introduced until 1999 (Ballantyne 2003). 
Searching other resources 
We further evaluated the reference lists of included studies and of relevant review articles identified by 
the search. To identify unpublished studies, we searched the online conference proceedings of annual 
meetings of the American Urological Association (www.auanet.org) and the European Association of 
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Data collection and analysis 
Selection of studies 
Three review authors (BR, OMA, JB) independently assessed relevant titles and abstracts of records 
identified by the literature search to determine which studies should be assessed further. Three 
review authors (BR, OMA, JB) investigated 
all potentially relevant records as full text, mapped records to unique studies, and classified studies 
as included studies, excluded studies, studies awaiting classification, or ongoing studies, in 
accordance with the criteria for each provided in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011). We resolved any disagreement by  discussion and consensus or by 
recourse to a fourth review author (KG). We adapted a PRISMA flow diagram to demonstrate the 
process of study selection (Liberati 2009). 
Data extraction and management 
For studies that fulfil inclusion criteria, three review authors (BR, OMA, JB) independently extracted the 
following information, which is provided in the Characteristics of included studies tables: 
• Study design (e.g. parallel-group randomised trial) 
• Study dates (if dates were 
not available, this was 
reported) Study settings and 
country 
• Participant inclusion and exclusion criteria 
• Participant details and baseline 
demographics, such as age and sex 
Numbers of participants by study and 
by study arm 
• Details of relevant experimental and comparator interventions and conversion rates from 
robotic to open 
• Definitions of relevant outcomes and methods and timing of outcome measurement, as 
well as any relevant subgroups Study funding sources 
• Declarations of interest by primary investigators 
For dichotomous outcomes, we attempted to obtain numbers of events and totals for populations on a 
2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous 
outcomes, we attempted to obtain means and standard deviations or data necessary to calculate this 
information. For time-to-event outcomes, we attempted to obtain hazard ratios (HRs) with 
corresponding measures of variance or data necessary to calculate this information. 
We resolved all disagreements by consensus. 
Dealing with duplicate and companion publications 
In the event of duplicate publications, companion documents, or multiple reports of a primary study, we 
maximised the yield of information by mapping all publications to unique studies and collating all 
available data. We used the most complete data set aggregated across all known publications. In case 
of doubt, we gave priority to the publication reporting the longest follow-up associated with our primary 
or secondary outcomes. 
 
Assessment of risk of bias in included studies 
Two review authors (BR, OMA) independently assessed the risk of bias of each included 
study and resolved all disagreements by consensus. 
We assessed risk of bias using Cochrane’s ‘Risk of bias’ assessment tool for the following 
domains (Higgins 2011):  
• Random sequence generation (selection bias) 
• Allocation concealment (selection bias) 
• Blinding of participants and 
personnel (performance bias) 
• Blinding of outcome 
assessment (detection bias) 




















For detection bias, we evaluated the risk of bias separately for each outcome. We regarded 
outcomes such as transfusion requirement and hospital stay as objective, and, if reported, we 
judged these studies as low risk. If studies did not report these outcomes, we judged them as 
unclear risk. 
For attrition bias, we evaluated risk of bias separately for quality of life. We combined the outcomes 
major and minor postoperative complications, hospital stay, transfusion requirement, and positive 
margin rates into a single group for attrition bias. 
 
Measures of treatment effect 
We used Review Manager 5 (RevMan 5) (RevMan) to analyse the data. We expressed dichotomous 
outcomes as risk ratios (RRs) with 95% confidence intervals (CIs). For time-to-event outcomes, we 
calculated the hazard ratio with 95% CI. We expressed continuous data as mean differences (MDs) or 
standardised mean differences (SMDs) (if the same outcome was evaluated by different tools) with 95% 
CIs. 
 
Unit of analysis issues 
Parallel-group designs were to be analysed. The unit of analysis was the individual participant. In 
the event we identified trials with more than two intervention groups for inclusion in the review, we 
handled these in accordance with guidance provided in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011). 
 
Dealing with missing data 
When data were missing, we contacted corresponding authors of the trials (Bochner 2015; Nix 2010; 
Parekh 2013; Parekh 2018). We had received no response from the corresponding authors of 
individual trials at the time of submission of this review. We imputed missing standard deviations in 
accordance with guidance provided in the Cochrane Handbook for 
 
Systematic Reviews of Interventions (Higgins 2011). We imputed means and standard deviations from 
median and range in accordance with guidance provided in Hozo 2005. 
Assessment of heterogeneity 
In the event of excessive heterogeneity unexplained by subgroup analyses, we did not report outcome 
results as the pooled effect estimate in a meta-analysis. 
We identified heterogeneity by using a Chi² test on N-1 degrees of freedom, with an 
alpha of 0.05 for statistical significance, and using the I² statistic (Higgins 2003). We 
interpreted the I² statistic as follows: 
• 0% to 40%: may not be important 
• 30% to 60%: may 
indicate moderate 
heterogeneity  
• 50% to 90%: may 
indicate substantial 
heterogeneity  
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heterogeneity 
Assessment of reporting biases 
We planned to obtain study protocols to evaluate studies for reporting bias. We did not formally 
perform funnel plot analysis, as the review included only five trials. 
Data synthesis 
We summarised data using a random-effects model. We interpreted random-effects meta-analyses 
with due consideration of the whole distribution of effects. In addition, we performed statistical analyses 
according to the statistical guidelines provided in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011). For dichotomous outcomes, we used the Mantel-Haenszel method; for 
continuous outcomes, we used the inverse variance method; and for time-to-event outcomes, we used 
the generic inverse variance method. We used RevMan software to perform analyses. 
GRADE and ‘Summary of findings’ table 
We presented the overall quality of evidence for each outcome according to the GRADE 
approach, which takes into account five criteria related not only to internal validity (risk of bias, 
inconsistency, imprecision, publication bias), but 
also to external validity, such as directness of results (Guyatt 2008). Two review authors (BR, OMA) 
independently rated the quality of evidence for each outcome as ‘high’, ‘moderate’, ‘low’, or ‘very low’, 
using GRADEpro GDT. We 
resolved any discrepancies by consensus. We presented a summary of evidence for the main 
outcomes in a ‘Summary of findings’ table, which provides key information about the best 
estimate of the magnitude of effect in relative terms and absolute differences for each relevant 
comparison of alternative management strategies; numbers of participants and studies 
addressing each important outcome; and the rating of overall confidence in effect estimates for 
each outcome (Guyatt 2011). 
Main outcomes for ‘Summary of findings’ table 
We have presented a ‘Summary of findings’ table (Table 1) to report the following outcomes listed 
according to priority: 
• Time to recurrence 
• Major postoperative 
complications (class III to V) 
(Dindo 2004)  
• Minor postoperative 
complications (class I and II) 
(Dindo 2004)  
• Length of hospital stay (days) 
 Quality of life  
 Positive margins (%) 
• Q 
Subgroup analysis and investigation of heterogeneity 
We attempted to perform subgroup analyses to explore possible sources of heterogeneity. We 
considered the following subgroups: 
• Participant age (younger than 60 years 
vs 60 years of age and older)  
• Participant body mass index (< 30 
kg/m² vs ? 30 kg/m²) 
• Pathological stage (? pT2 disease vs pT3 disease) 
• Surgeon’s level of experience (less than expert vs expert, as defined by trial authors) 
We planned to test for subgroup differences using RevMan 5 to compare subgroup 
analyses if we found sufficient studies (RevMan). We could not do this with the information 
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Results 
Description of studies 
We identified 332 references through electronic searches of the different databases. 
We retrieved a total of 32 references for further detailed assessment. We excluded 26 references for 
the reasons listed in the Characteristics of excluded studies table. We found that seven references on 
five randomised controlled trials (RCTs) fulfilled the review inclusion criteria (see Characteristics of 
included studies). Two trials published outcomes in two separate publications (Bochner 2015; Parekh 
2013). We have presented the reference flow in Figure 1 . 
Included studies 
Study design and setting 
Five trials were published between 2010 and 2018: 
• Nix 2010 reported the first trial of RARC versus ORC. Researchers conducted this 
study at the University of North Carolina in the USA and randomised 21 participants 
to an open approach and 20 to a robotic-assisted laparoscopic approach. The study 
had a noninferiority design, and its primary outcome was lymph node yield. 
• The RAZOR trial (a prospective, multicentre, randomised trial of open vs robotic 
radical cystectomy) was the largest and most recently published trial (Parekh 2018). 
It was conducted at 15 academic centres in the USA and randomised 159 and 153 
participants to RARC and ORC cohorts, respectively (Parekh 2018). After 
exclusions, 150 participants were included in the RARC cohort and 152 participants 
in the ORC cohort, in the per-protocol analysis set (Parekh 2018). The study used a 
noninferiority design and included a primary outcome of progression-free survival at 
two years. 
• Parekh 2013 reported the results of a preceding pilot trial leading up to the RAZOR 
trial that was conducted at the University of Texas at San Antonio in the USA. Study 
authors randomised 20 participants each to RARC and ORC and reported 
oncological outcomes and quality of life outcomes - in two separate publications 
(Parekh 2013). This study had no specific primary endpoint aside from establishing 
randomisation. 
• Bochner 2015 reported the results of a single-institution, randomised trial conducted at 
Memorial Sloan Kettering Cancer Center in the USA. Investigators randomised 60 and 58 
participants to RARC and ORC cohorts, respectively. The study was described as an 
expertise-based trial. Study authors reported oncological outcomes in a second 
publication. 
• Khan 2016 reported the results of a single-institution, three-armed, randomised trial 
conducted at Guy’s Hospital, in London, United Kingdom, that randomised 20 participants 
each to RARC, ORC, and (pure) laparoscopic cystectomy. This study was described as an 
expertise-based trial. 
Participants 
The total numbers of participants included in the ORC and RARC cohorts were 270 and 
271, respectively. Most participants in both the ORC (221; 82%) and RARC (226; 83.4%) 
groups were men. Three studies reported 
demographic data using the median (Bochner 2015; Parekh 2013; Parekh 2018) and two using the 
mean (Khan 2016; Nix 2010). The mean age of participants in the ORC cohort ranged between 66.6 
years and 69.2 years. The mean age of participants in the RARC cohort ranged between 67.4 years 
and 68.6 years. The median age of participants in the ORC cohort ranged between 64.5 years and 65 
years. The median age of participants in the RARC cohort ranged between 66 years and 69.5 years. 
The mean body mass index (BMI) (in kg/m²) of participants in the ORC cohort ranged between 27.4 
and 28.4. The mean BMI (kg/m²) of participants in the RARC cohort ranged were similar at 27.5. The 
median BMI (kg/m²) of participants in the ORC cohort ranged between 24.9 and 31.7, and the median 
BMI (kg/m²) of participants in the RARC cohort ranged between 25 and 30.8. 
Interventions and comparators 
All five studies compared ORC to RARC (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; 
Parekh 2018); one trial included an arm of laparoscopic radical cystectomy (Khan 2016). Four 
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Parekh 2018). One study performed urinary diversion at the discretion of the surgeon and did 
not explicitly report the type (Parekh 2013). In the ORC cohort, urinary diversion was ileal 
conduit, neobladder, and continent cutaneous type in 194 (72%), 73 (27%), and 3 (1%) 
participants, respectively. In the RARC cohort, urinary diversion was ileal conduit, neobladder, 
and continent cutaneous type in 191 (70.6%), 79 (29%), and 1 (0.4%) participant, respectively. 
All five trials performed a pelvic lymph node 
dissection (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013; Parekh 2018). We have summarised the 
inclusion criteria for each study in the Characteristics of included studies table. 
Outcomes 
Bochner 2015 reported on patient-reported outcomes (PROs) of quality of life (QoL) using the 
validated European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire Core 30 (QLQ-C30) survey. Khan 2016 evaluated QoL using the validated Functional 
Assessment of Cancer Therapy –Bladder (FACT-Bl) scale v4 questionnaire. Parekh 2013 and Parekh 
2018 evaluated QoL using the validated Functional Assessment of Cancer Therapy 
–Vanderbilt Cystectomy Index (FACT–VCI) questionnaire. 
Funding 
Parekh 2018 was funded by the National Institutes of Health National Cancer Institute. 
Bochner 2015 was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers at 
Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer, and the Michael and Zena 
Wienerfor Therapeutics Program in Bladder Cancer. Study sponsors were involved in the design and 
conduct of the study; in collection, analysis, management, and interpretation of the data; and in 
preparation, review, and approval of the manuscript. 
Khan 2016 was supported by the National Institute for Health Research (NIHR) Biomedical Research 
Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London. Study 
authors acknowledge support from the NIHR Biomedical Research Centre, the Medical Research 
Council Centre for Transplantation, King’s Health Partners, Guy’s and St. Thomas’ Charity, the School 
of Surgery, the London Deanery, the Royal College of Surgeons of England, Intuitive Surgical, the 
Urology Foundation, Olympus, EU-FP7, ProstateCancer UK, the Technology Strategy Board, and the 
Vattikuti Foundation. 
The remaining two studies did not report funding (Nix 2010; Parekh 2013). 
Excluded studies 
We excluded 26 of these publications. All of these studies were nonrandomised comparative studies 
comparing 
ORC and RARC (Excluded studies). We have documented further details of individual studies in 
the Characteristics of excluded studies table. 
Risk of bias in included studies 
We have summarised the methodology and risk of bias of individual trials in the Characteristics of 
included studies table. We have summarised the risk of bias for individual trials in Figure 2. 
Allocation (selection bias) 
Random sequence generation 
We judged all five trials to have low risk of bias for random sequence allocation (Bochner 2015; 
Khan 2016; Nix 2010; Parekh 2013; Parekh 2018). 
Allocation concealment 
Nix 2010 performed a randomisation schema with five sequential participants undergoing one 
approach before alternating with another approach. Their concealment would have to be 
deemed inadequate and hence judged to be 
at high risk of bias. The remaining trials had low risk of bias in their allocation concealment strategy 
(Bochner 2015; Khan 
2016; Parekh 2013; Parekh 2018). 
Blinding (performance bias and detection bias) 
Performance bias 
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personnel were blinded for any of the review outcomes. We therefore judged all included studies to be 
at high risk of performance bias. 
Detection bias 
Time to recurrence 
Two trials reported on recurrence-free survival (Bochner 2015; Parekh 2018). Due to the lack of 
blinding of outcome assessors, we judged Parekh 2018 to be at high risk of detection bias for 
recurrence-free survival (Parekh 2018). 
We judged one trial as having unclear risk of detection bias for recurrence-free survival, 
as trial authors did not explicitly state who assessed this outcome (Bochner 2015). 
Complications (all grades) 
Three included studies were unblinded; we therefore judged them to be at high risk of detection bias for 
complications (Bochner 2015; Khan 2016; Parekh 2018). Two studies did not report who the 
assessors were and whether blinding had taken place; hence we judged them to be at unclear risk of 
detection bias for complications (Nix 2010; Parekh 2013). 
Quality of life 
In all four included studies, participants were not blinded; we therefore judged these trials to be 
at high risk of detection bias for the self-assessed outcome of quality of life survey (Bochner 
2015; Khan 2016; Parekh 2013; Parekh 2018). 
One study did not report quality of life data (Nix 2010). 
Positive margin rates, hospital stay, and transfusion rates 
The review authors opined that positive margin rates, hospital stay, and transfusion rates 
were unlikely to be affected by the blinding status of outcome assessors in these trials. We 
therefore judged all five studies to be at low 
risk of detection bias for positive surgical margin rates and hospital stay (Bochner 2015; Khan 2016; Nix 
2010; Parekh 2013; Parekh 2018). 
Nix 2010, Bochner 2015, and Khan 2016 did not report on transfusion rates. We judged Parekh 2018 
and Parekh 2013 to be at low risk of detection bias for transfusion rates. 
Incomplete outcome data (attrition  bias) 
Quality of life 
We judged four studies to be at high risk of attrition bias for quality of life survey results, given 
that a large proportion of participants (> 20%) failed to provide information (Bochner 2015; 
Khan 2016; Parekh 2013; Parekh 2018). 
Major and minor postoperative complications, transfusion requirements, hospital stay, and 
positive margins 
We rated all studies as having low risk of attrition bias with near complete inclusion of 
randomised participants in analyses for these outcomes (Bochner 2015; Khan 2016; Nix 
2010; Parekh 2013; Parekh 2018). 
Time to recurrrence 
We rated Bochner 2015 as having low risk of attrition bias, with all randomised participants included in 
the analysis. We rated Parekh 2018 as having unclear risk of attrition bias. 
Selective reporting (reporting bias) 
Four studies had protocols registered in a trials registry (Bochner 2015; Khan 2016; Parekh 2013; 
Parekh 2018). We noted no obvious selective reporting for the outcomes of this review in these studies, 
and hence we judged them as having low risk of reporting bias. We were unable to find a protocol for 
the Nix 2010 trial. Therefore, we judged this trial as having an unclear risk of reporting bias. 
Other potential sources of bias 
We identified no other biases in any of the other included trials (Bochner 2015; Khan 2016; Nix 2010; 
Parekh 2013; Parekh 2018). 
 
Effects of interventions Primary  outcomes Time to recurrence 
RARC may result in a similar time to recurrence as ORC (hazard ratio (HR) 1.05, 95% confidence interval 










This article is protected by copyright. All rights reserved. 
1.43); 2 trials; low-certainty evidence) (Figure 3). We downgraded the certainty of evidence for study 
limitations and imprecision (Analysis 1.1; Summary of findings table 1). In absolute terms, this 
corresponds to 16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more). The control 
event rate at 5 years was based on an overall recurrence rate of 25/58 (43.1%) in the ORC arm 
reported in Bochner 2015. 
Major complications (Clavien grades 3 to 5) 
RARC may result in similar rates of major complications as ORC (risk ratio (RR) 1.06, 95% CI 
0.76 to 1.48); 5 trials; low-certainty evidence) (Figure 4). This corresponds to 11 more major 
complications per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the 
certainty of evidence for study limitations and imprecision (Analysis 1.2; Summary of findings 
table 1). 
Five trials reported on complications. Three studies reported the total number of Clavien grade 3 to 
5 complications ( Bochner 2015; Khan 2016; Parekh 2018). The other two studies reported 
specific complications (Nix 2010; Parekh 2013 
), based on which the review authors were able to classify complications by adopting the Clavien-
Dindo grading system (Dindo 2004). 
Secondary outcomes 
Minor complications (Clavien grades 1 and 2) 
We are very uncertain whether RARC results in fewer minor complications than ORC (RR 0.82, 
95% CI 0.58 to 1.17; 4 trials; very low-certainty evidence). This corresponds to 80 fewer minor 
complications per 1000 participants (95% CI 186 fewer to 75 more). We downgraded the 
certainty of evidence for serious study limitations and very serious imprecision (Analysis 1.3; 
Summary of findings table 1). 
Transfusion rate 
RARC probably results in fewer transfusions than ORC (RR 0.58, 95% CI 0.43 to 0.80; 2 
trials; moderate-certainty evidence). This corresponds to 193 fewer transfusions per 1000 
participants (95% CI 262 fewer to 92 fewer). We downgraded the certainty of evidence for 
study limitations (Analysis 1.4; Summary of findings table 1). Only two studies reported on 
transfusion rates (Parekh 2013; Parekh 2018). 
Length of hospital stay (days) 
All five trials provided information on hospital stay. One trial reported similar mean hospital stays 
of 5.1 days and 6 days in the RARC and ORC cohorts but did not report a standard deviation (Nix 
2010). We therefore imputed the standard deviation. Two trials reported hospital stay in median 
and range values (Parekh 2013; Parekh 2018). We therefore imputed the mean and standard 
deviation for these trials. Two studies provided explicit data on mean hospital stay 
for meta-analysis (Bochner 2015; Khan 2016). 
Overall, we found that RARC may reduce mean hospital stay slightly (mean difference (MD) -0.67, 95% 
CI -1.22 to -0.12; 5 trials; low-certainty evidence). We downgraded the quality of evidence for study 
limitations and imprecision ( Analysis 1.5; Summary of findings table 1). 
Quality of life 
RARC may result in similar quality of life when compared with ORC (standard mean difference (SMD) 
0.08, 95% CI: 0.32 lower to 0.16 higher; 3 trials; low-certainty evidence). We downgraded the certainty of 
evidence for study limitations and imprecision (Analysis 1.6; Summary of findings table 1). 
Four studies reported on quality of life (QoL) outcomes (Bochner 2015; Khan 2016; Parekh 
2013; Parekh 2018). One trial used the European Organisation for Research and Treatment 
of Cancer (EORTC) Quality of Life 
Questionnaire Core 30 (QLQ-C30) survey (Bochner 2015). In this trial, data from the Global 
Health status domain were used for analysis, as this information reflected overall health status. 
One trial used the Functional Assessment of Cancer Therapy –Bladder (FACT-Bl) scale v4 and 
covered physical, emotional, and social well-being, as well as questions specific to bladder 
cancer (Khan 2016). Two trials used the Functional Assessment of Cancer Therapy –Vanderbilt 
Cystectomy Index (FACT–VCI) questionnaire ( Parekh 2013; Parekh 2018). The standardised 
mean difference was used in view of the different QoL assessment tools used. One study 
reported QoL in median and range values (Parekh 2013). We therefore imputed mean and 










This article is protected by copyright. All rights reserved. 
Positive margin rates 
RARC may result in similar positive margin rates when compared to ORC (RR 1.16, 95% CI 0.56 to 
2.40; 5 trials; low- certainty evidence). This corresponds to eight more positive margins per 1000 
participants (95% CI 21 fewer to 67 more). 
We downgraded the certainty of evidence for study limitations and imprecision (Analysis 1.7; 
Summary of findings table 1). We were unable to conduct any of the preplanned secondary analyses 
due to lack of suitable data. 
Discussion 
Summary of main results 
There may be little to no difference in time to recurrence and in risk of major complications 
between the two surgical approaches to treat muscle-invasive bladder cancer. We are very 
uncertain whether RARC reduces the rate of minor complications. There may be little to no 
difference in quality of life and positive margin rates. RARC probably reduces transfusions 
substantially and may reduce length of stay slightly. 
Overall completeness and applicability of evidence 
Follow-up of the included trials is generally limited; only one trial has reported longer-term 
follow-up for the outcome of recurrence-free survival at a median follow-up of 4.9 years 
(Bochner 2015). Another trial reported on progression- free survival at two years (Parekh 2018). 
Review authors judged this trial to have high risk of performance and detection bias for 
recurrence-free survival. One small trial provided data on recurrence rates and overall and 
disease- 
specific mortality at 12 months (Khan 2016). We judged this trial to have high risk of performance, 
detection, attrition, and reporting bias. Follow-up was very short, at 12 months, further emphasising 
the lack of vital long-term oncological data derived from randomised controlled trials (RCTs) 
comparing open radical cystectomy (ORC) and robotic-assisted radical cystectomy (RARC). 
All studies reported on complication rates. However, two studies did not demonstrate clear 
categorisation into minor and major complications using the Clavien-Dindo grading system, as 
suggested by this review (Nix 2010; Parekh 2013). We therefore examined individual complications 
reported by these trials and classified them using the Clavien-Dindo grading system. Although data 
show no obvious differences between ORC and RARC for major complications, the outcomes again 
were of low quality, suggesting significant uncertainty of the results, and hence must be viewed with 
caution. 
For the outcomes "hospital stay" and "quality of life", three studies reported unfavourable metrics 
and statistical methods (e.g. median, no standard deviations reported for means) for meta-analysis 
(Nix 2010; Parekh 2013, Parekh 2018). The review authors therefore imputed these data. 
Quality of the evidence 
We rated the certainty of evidence as low for all outcomes, except transfusion rates and hospital stay. 
We consistently downgraded evidence for a combination of study limitations, most often performance 
bias (lack of blinding of participants and personnel) and detection bias (lack of blinding of outcome 
assessors). We also frequently downgraded evidence for imprecision due to wide confidence intervals 
that indicated no effect but also included the possibility of clinically relevant benefit or harm. 
Potential biases in the review process 
We performed this systematic review in accordance with current Cochrane standards. The review 
nevertheless has the following limitations: 
• The review authors cannot be absolutely certain if we missed identifying any other 
potential randomised trials comparing ORC and RARC in our search, although we think 
this is unlikely. 
• We excluded from the meta-analysis some of the data reported by individual studies 
due to lack of appropriate data points. We contacted the authors of these individual 
studies but were not successful in obtaining additional data. We chose to impute data 
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Agreements and disagreements with other studies or reviews 
We identified five relevant systematic reviews of randomised and nonrandomised controlled trials 
comparing robotic and open radical cystectomy (Ishii 2014; Novara 2015; Tang 2014; Yuh 2015; 
Sathianathen 2018). These reviews used pooled data derived across all study designs, and none 
considered evaluation of the quality of evidence as defined by GRADE. 
Yuh 2015 performed a cumulative analysis of oncological and functional outcomes of robotic-
assisted radical cystectomy (RARC). This review identified 65 surgical series and 22 comparative 
studies reporting on pathological, oncological, and functional outcomes of RARC. Two trials in the 
review were randomised trials (Nix 2010; Parekh 2013). We included both of these studies in our 
review. A majority of the studies included in this review were retrospective studies. No certainty of 
evidence was assessed. The review identified two nonrandomised comparative studies that 
reported similar survival outcomes between ORC and RARC (Khan 2012; Nepple 2013). Review 
authors suggested caution when interpreting these results due to short follow-up, small series, and 
study limitations. 
Novara 2015 performed a cumulative analysis of perioperative outcomes and postoperative 
complications of RARC. This review identified 70 surgical series and 23 comparative studies. 
Three trials included in the review were randomised trials (Bochner 2015; Nix 2010; Parekh 
2013). We have included these three studies in our review. A majority of studies included in 
the Novara review were retrospective studies. Review authors categorised individual studies 
to the 2011 level of evidence and IDEAL recommendations and scrutinised the quality of 
reporting of complications of individual studies using the Martin criteria (Martin 2002). They 
performed no other quality assessment of individual studies. These review authors reported 
90-day complication rates of any grade and found that 90-day grade 3 complication rates were 
lower for RARC, whereas high-grade complication and mortality rates were similar. It is 
unclear from the review how the review authors differentiated between grade 3 complications 
and high-grade complications. The analysis for grade 3 complications did not include any of 
the RCTs. The analysis for 
high-grade complications included one RCT (Bochner 2015). The RCT included in this analysis 
contributed 19.3% to the study weight. 
Tang 2014 performed a systematic review that included 13 studies comparing RARC and ORC. One 
trial in the review was a randomised trial (Nix 2010). We have included this study in our review. 
These review authors reported perioperative 
and pathological outcomes and complications. Review authors pooled data across all study designs. They 
rated the level of 
evidence (LOE) of included studies according to criteria provided by the Centre for Evidence-Based 
Medicine in Oxford, UK. They assessed risk of bias of the RCT using the Jadad scale and of 
observational studies using the Newcastle–Ottawa scale. Pooled analysis favoured the RARC cohort 
for overall complication rate. Nix 2010, the only RCT included in the analysis, contributed only 5.5% to 
the study weight. 
Ishii 2014 performed a systematic review that included seven studies comparing RARC and ORC. 
Two trials in the review were randomised trials (Nix 2010; Parekh 2013). We have included both of 
these studies in our review. Review authors assessed the methodological quality of these included 
studies in line with the Cochrane Handbook for Systematic Reviews of Interventions. The primary 
outcome of this study was complication rates. Pooled analysis favoured the RARC 
cohort for major complication rates. Analysis for major complications included one RCT (Parekh 
2013), which contributed to 6.7% to the study weight. 
Sathianathen 2018 has published the most recent and highest-quality review to date. 
Methodolgical hallmarks include an a priori registered protocol with predefined primary 
outcomes, a comprehensive search of multiple data sources, and study inclusion irrespective 
of language of publication status and use of GRADE to assess the quality of evidence on a 
per-outcome basis. Instead of recurrence-free survival as a time-to-event outcome used in 
our review, these review authors analysed risk of recurrence as a dichotomous outcome. 
They rated findings as moderate-quality evidence, which is more optimistic than our rating of 
low-quality evidence, while qualifying that there is little to no difference between the two 
approaches. What our review further adds is a summary of findings table (Summary of 
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Authors' conclusions 
 
Implications for practice 
Based on the findings of this review, oncological outcomes and rates of major complications may be 
similar for both approaches. Robotic-assisted cystectomy probably reduces transfusion needs 
substantially and may slightly reduce length of hospital stay. We are uncertain whether minor 
complications are also reduced. We were unable to address how patients’ 
and surgeons’ characteristics may affect these outcomes. Furthermore, this review was not 
designed to address resource utilisation or cost-effectiveness. 
Implications for research 
This review is based on five relatively small trials with methodological limitations that provided 
low-quality evidence  for most outcomes. Only one trial has provided long-term oncological 
outcomes (Bochner 2015). We see the following research needs: 
• Investigators of existing trials should report longer-term results for longer-
term oncological outcomes.  
• Researchers should assess the influence of patient factors such as 
pathological stage and body habitus.  
• Studies should establish the impact of surgeon factors such as skills and 
experience on outcomes. 
• Most instances of urinary diversion reported in included trials were performed through an 
extracorporeal approach. Future trials should evaluate outcomes between open radical 
cystectomy and robotic-assisted radical cystectomy performed through intracorporeal 
urinary diversions. 
• Any future trial should apply widely accepted methodological safeguards against bias 
and should transparently report them. 
 
Additional information 
Appendix 1, available as supplementary online material, includes search strategies, characteristics of 
studies, data and analyses table, sources of support, contributions of authors, declarations of interest, 
differences between protocol and review, and published notes. 
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Summary of findings table 
 
Robotic-assisted laparoscopic vs open radical cystectomy for bladder cancer in adults 
Patient or population: bladder cancer in adults 
Setting: tertiary care centres in the United States and the United Kingdom 
Intervention: robotic-assisted laparoscopic cystectomy 
Comparison: open radical cystectomy 







































431 per 1000 16 more per 
1000 

















185 per 1000 11 more per 
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1000 
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units of packed 
red blood cells 
(262 fewer to 
92 fewer) 
Hospital stay 








5.1 to 11.9 
days 
MD 0.67 days 
lower 
(1.22 lower to 
0.12 lower) 
Quality of life 
(higher scores 
indicate better 





quality of life 
instruments 












of life) was 0 
SD 
SMD 0.08 SD 
lower 


















48 per 1000 8 more per 
1000 
(21 fewer to 
67 more) 
*The risk in the intervention group (and its 95% confidence interval) is based on the 
assumed risk in the comparison group and the relative effect of the intervention (and its 
95% CI). 
 
CI: confidence interval; HR: hazard ratio; MD: mean difference; RCT: randomised 
controlled trial; RR: risk ratio; SMD: standardised mean difference. 
GRADE Working Group grades of evidence. 
High certainty: We are very confident that the true effect lies close to that of the 
estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: the true effect 
is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different. 
Low certainty: Our confidence in the effect estimate is limited: the true effect may be 
substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: the true effect 
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Footnotes 
1The control event rate at 5 years was based on an overall recurrence rate of 25/58 (43.1%) in 
the ORC arm reported in Bochner 2015 
aDowngraded by one level for study limitations; risk of performance, detection, and attrition 
bias. 
bDowngraded by one level for imprecision: wide confidence intervals consistent with both no 
effect and clinically important benefit or harm. 
cDowngraded by one level for study limitations; risk of performance and detection bias. 
dDowngraded by two levels for very serious imprecision: wide confidence interval consistent 
with small benefit, no effect, and small harm. 
eDowngraded by one level for imprecision: wide confidence intervals consistent with both no 
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Figure 2: Risk of bias summary: review authors’ judgements about each risk of bias item for 
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Figure 3 (Analysis1.1) 
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Figure 4 (Analysis1.2) 
Forest plot of comparison: 1 Primary outcome, outcome: 1.1 Major postoperative complication rates 
(Clavien 3 to 5). 
 
 
 
 
